The CSO-treated MCAO rats had significantly fewer C3d/GFAP-positive cells than did the rats in the MCAO-Con group (*p < 0.05), and the number of S100A10/GFAP-positive cells in the MCAO-CSO group was significantly greater than in the MCAO-Con group (*p < 0.05). The gene discussed is S100A10; the disease is craniosynostosis.